FDA Approval in TGCT, Breakthrough Designation in Melanoma, and More

FDA Approval in TGCT, Breakthrough Designation in Melanoma, and More

Publication date: Aug 12, 2019

Kristi Rosa reports on an FDA approval in tenosynovial giant cell tumor, a breakthrough therapy designation in melanoma, encouraging findings in trials in bladder cancer, lung cancer, and a cell-free DNA assay.

Concepts Keywords
Africa Disease
Alk Tumors
Amazon Tumor
ASEC Metastatic disease
Asian Metastatic ethereal carcinoma
Assay Microsatellite stable disease
Asthma Small lung disease
Beer Chemotherapy
Benfica Surgery
Binary Immunotherapy
Bladder Cancer Clinical medicine
Breakthrough Therapy Cancer treatments
Cancer RTT
Carcinoma Tyrosine kinase receptors
Chemotherapy Monoclonal antibodies
Chronic Diseases Lung cancer
Cisplatin Melanoma
Clinical Trials Microsatellite instability
Cohort Anaplastic lymphoma kinase
Colorado Durvalumab
Concordance Chemotherapy
Diabetes
DSO
Egypt
Exxon
Fat
FDA
Garden
Harmony
Immunotherapy
Inhibitor
Locks
Lung
Lung Cancer
Lung Disease
Malignant Tumor
Mech
Melanoma
Metastatic
Microsatellite
Morbidity
Mutation
Nail
PDO
Placebo
Platinum
Primary Endpoint
Radiology
Raffi
Receptor
Siri
Small Molecule
Synovial
Tara
Tennis
Tesla
Tumor
War

Semantics

Type Source Name
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma
disease MESH tenosynovial giant cell tumor
disease DOID tenosynovial giant cell tumor
disease MESH bladder cancer
disease DOID bladder cancer
pathway BSID Bladder Cancer
pathway BSID Bladder cancer
disease MESH lung cancer
disease DOID lung cancer

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *